| P2093 | author name string | Maria Mercedes Torres | |
| | Rafael E Andrade | |
| | Rocío López | |
| | Adriana Plata | |
| P2860 | cites work | HER-2 fluorescence in situ hybridization: results from the survey program of the College of American Pathologists | Q82741034 |
| | Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 |
| | Clinical application of the 70-gene profile: the MINDACT trial | Q28267891 |
| | American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer | Q33303529 |
| | Biology of HER2 and its importance in breast cancer | Q34428745 |
| | The epidermal growth factor receptor family: biology driving targeted therapeutics | Q34692233 |
| | Development of the 21-gene assay and its application in clinical practice and clinical trials | Q37079600 |
| | Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. | Q38483521 |
| | HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues | Q47612892 |
| | American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. | Q51925963 |
| | 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 |
| | Her2 amplification status in Iranian breast cancer patients: comparison of immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH). | Q54571759 |
| | HER2 testing in breast carcinoma: very low concordance rate between reference and local laboratories in Brazil. | Q54645114 |
| | Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message | Q73881583 |
| | Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831 | Q74239122 |
| | Concordance between central and local laboratory HER2 testing from a community-based clinical study | Q79791330 |
| | HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial | Q79816337 |
| | Comparison of HER2 detection methods between central and regional laboratories in Greece | Q79898072 |
| | HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab | Q80463670 |
| P4510 | describes a project that uses | immunohistochemistry | Q899285 |
| P433 | issue | 2 | |
| P921 | main subject | immunohistochemistry | Q899285 |
| P304 | page(s) | 108-114 | |
| P577 | publication date | 2013-04-01 | |
| P1433 | published in | Colombia Médica | Q22671430 |
| P1476 | title | Determination of the HER2 amplification status by in situ fluorescent hybridization and concordance with immunohistochemistry for breast cancer samples in Colombia | |
| P478 | volume | 44 | |